Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,432,312
  • Shares Outstanding, K 146,702
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 2,377 M
  • EBITDA $ 3,341 M
  • 60-Month Beta 0.16
  • Price/Sales 2.98
  • Price/Cash Flow 10.69
  • Price/Book 1.62

Options Overview Details

View History
  • Implied Volatility 32.30% (+2.71%)
  • Historical Volatility 42.91%
  • IV Percentile 23%
  • IV Rank 12.75%
  • IV High 64.86% on 04/09/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 2) 9.01 (4.77%)
  • Put/Call Vol Ratio 0.62
  • Today's Volume 955
  • Volume Avg (30-Day) 2,537
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 52,834
  • Open Int (30-Day) 55,926
  • Expected Range 179.98 to 198.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 34 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.28
  • Number of Estimates 21
  • High Estimate 4.03
  • Low Estimate 2.59
  • Prior Year 3.02
  • Growth Rate Est. (year over year) +8.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
160.36 +17.85%
on 01/20/26
202.41 -6.63%
on 02/06/26
+1.37 (+0.73%)
since 01/09/26
3-Month
154.20 +22.56%
on 11/11/25
202.41 -6.63%
on 02/06/26
+32.73 (+20.95%)
since 11/10/25
52-Week
110.04 +71.75%
on 04/09/25
202.41 -6.63%
on 02/06/26
+46.45 (+32.59%)
since 02/10/25

Most Recent Stories

More News
BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds

BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds

BIIB : 188.99 (-2.49%)
Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales

Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales

BIIB : 188.99 (-2.49%)
Stock Index Futures Climb After Tech Rout, Amazon Slips on CapEx Blowout

March S&P 500 E-Mini futures (ESH26) are up +0.58%, and March Nasdaq 100 E-Mini futures (NQH26) are up +0.69% this morning, rebounding after days of heavy selling as investors stepped in to buy the dip....

MARA : 7.66 (-4.96%)
MSTR : 133.00 (-3.93%)
NVDA : 188.54 (-0.79%)
AVGO : 340.44 (-1.02%)
BE : 148.70 (-4.17%)
KOG.O.DX : 367.850 (-1.93%)
MOH : 125.43 (-1.65%)
STLAP.FP : 6.227 (-2.04%)
MU : 373.25 (-2.67%)
ESH26 : 6,961.00 (-0.01%)
MSFT : 413.27 (-0.08%)
NOVOB.C.DX : 307.750 (-2.66%)
Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings

Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings

BIIB : 188.99 (-2.49%)
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 32.44 (+1.41%)
BIIB : 188.99 (-2.49%)
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersen The high-dose...

IONS : 84.29 (-0.59%)
BIIB : 188.99 (-2.49%)
1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky

1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky

ULTA : 679.28 (-2.44%)
NSC : 315.45 (+3.18%)
BIIB : 188.99 (-2.49%)
Jobs Reports Rate Full Attention

Monday U.S. Economic Lookahead Auto sales (Jan.) ISM manufacturing (Jan.) ...

GOOG : 318.63 (-1.78%)
MRK : 117.15 (-0.42%)
ABBV : 222.44 (-0.37%)
MUFG : 19.39 (+0.94%)
AER : 145.00 (+1.75%)
DIS : 109.96 (+2.64%)
MFG : 9.94 (+1.43%)
UI : 718.46 (+0.85%)
AMD : 213.57 (-1.12%)
LLY : 1,025.00 (-1.88%)
SHEL : 77.90 (+0.13%)
PM : 182.69 (+0.47%)
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activity Litifilimab...

BIIB : 188.99 (-2.49%)
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease

BIIB : 188.99 (-2.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 200.54
2nd Resistance Point 198.13
1st Resistance Point 193.56
Last Price 188.99
1st Support Level 186.58
2nd Support Level 184.17
3rd Support Level 179.60

See More

52-Week High 202.41
Last Price 188.99
Fibonacci 61.8% 167.12
Fibonacci 50% 156.23
Fibonacci 38.2% 145.33
52-Week Low 110.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar